Moleculin Historical Income Statement

Stocks . USA . 
Stock . Moleculin Biotech
MBRX Stock  USD 2.73  0.10  3.53%   
Historical analysis of Moleculin Biotech income statement accounts such as Selling General Administrative of 6.9 M can show how well Moleculin Biotech performed in making a profits. Evaluating Moleculin Biotech income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Moleculin Biotech's future profits or losses.
Cash Flow   Balance Sheet     Income Statement
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Moleculin Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Moleculin Biotech is a good buy for the upcoming year.
  
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.

About Moleculin Income Statement Analysis

Moleculin Biotech Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Moleculin Biotech shareholders. The income statement also shows Moleculin investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).
Balance Sheet
Statement
Details
Cash Flow
Statement
Details
Financial
Indicators
Details
Valuation
Indicators
Details

Moleculin Biotech Income Statement Chart

At this time, Moleculin Biotech's Interest Expense is fairly stable compared to the past year. Cost Of Revenue is likely to rise to about 143.1 K in 2024, whereas Interest Income is likely to drop slightly above 965.1 K in 2024.
Interest Expense  Selling General Administrative  Selling And Marketing Expenses  Other Operating Expenses  Research Development  
Add Fundamental

Interest Expense

The cost incurred by an entity for borrowed funds, including loans, bonds, or lines of credit.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Moleculin Biotech. It is also known as Moleculin Biotech overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.
Most accounts from Moleculin Biotech's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Moleculin Biotech current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Moleculin Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For more information on how to buy Moleculin Stock please use our How to Invest in Moleculin Biotech guide.At this time, Moleculin Biotech's Interest Expense is fairly stable compared to the past year. Cost Of Revenue is likely to rise to about 143.1 K in 2024, whereas Interest Income is likely to drop slightly above 965.1 K in 2024.
 2021 2022 2023 2024 (projected)
Depreciation And Amortization260K222K127K120.7K
Interest Income306K240K1.2M965.1K

Moleculin Biotech income statement Correlations

Interest Income
Depreciation And Amortization
Selling General Administrative
Selling And Marketing Expenses
Other Operating Expenses
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Income Before Tax
Total Other Income Expense Net
Net Income
Income Tax Expense
Net Interest Income
Reconciled Depreciation
Non Operating Income Net Other
Interest Income
-0.370.190.360.23-0.21-0.15-0.30.23-0.310.23-0.160.33-0.210.550.030.310.54
Depreciation And Amortization
-0.37-0.76-0.96-0.760.770.740.75-0.740.78-0.760.74-0.380.72-0.22-0.43-0.63-0.71
Selling General Administrative
0.19-0.760.81.0-0.97-0.96-0.970.99-0.971.0-0.950.47-0.9-0.160.590.80.85
Selling And Marketing Expenses
0.36-0.960.80.8-0.75-0.72-0.740.79-0.770.8-0.720.46-0.680.160.330.660.73
Other Operating Expenses
0.23-0.761.00.8-0.98-0.96-0.971.0-0.971.0-0.950.5-0.9-0.150.610.830.88
Operating Income
-0.210.77-0.97-0.75-0.980.990.99-0.970.99-0.980.98-0.430.950.14-0.72-0.83-0.88
Net Income From Continuing Ops
-0.150.74-0.96-0.72-0.960.990.97-0.960.97-0.961.0-0.30.980.09-0.73-0.77-0.81
Ebit
-0.30.75-0.97-0.74-0.970.990.97-0.971.0-0.970.97-0.480.930.11-0.7-0.85-0.92
Research Development
0.23-0.740.990.791.0-0.97-0.96-0.97-0.971.0-0.940.5-0.9-0.150.620.830.89
Ebitda
-0.310.78-0.97-0.77-0.970.990.971.0-0.97-0.970.97-0.480.930.09-0.69-0.85-0.92
Total Operating Expenses
0.23-0.761.00.81.0-0.98-0.96-0.971.0-0.97-0.950.5-0.9-0.150.610.830.88
Income Before Tax
-0.160.74-0.95-0.72-0.950.981.00.97-0.940.97-0.95-0.260.990.07-0.78-0.75-0.8
Total Other Income Expense Net
0.33-0.380.470.460.5-0.43-0.3-0.480.5-0.480.5-0.26-0.13-0.41-0.060.670.67
Net Income
-0.210.72-0.9-0.68-0.90.950.980.93-0.90.93-0.90.99-0.13-0.06-0.8-0.69-0.76
Income Tax Expense
0.55-0.22-0.160.16-0.150.140.090.11-0.150.09-0.150.07-0.41-0.06-0.15-0.29-0.02
Net Interest Income
0.03-0.430.590.330.61-0.72-0.73-0.70.62-0.690.61-0.78-0.06-0.8-0.150.430.48
Reconciled Depreciation
0.31-0.630.80.660.83-0.83-0.77-0.850.83-0.850.83-0.750.67-0.69-0.290.430.9
Non Operating Income Net Other
0.54-0.710.850.730.88-0.88-0.81-0.920.89-0.920.88-0.80.67-0.76-0.020.480.9
Click cells to compare fundamentals

Moleculin Biotech Account Relationship Matchups

High Positive Relationship

Other Operating Expenses
+ 1.0
Selling General Administrative
Total Operating Expenses
+ 1.0
Selling General Administrative
Research Development
+ 1.0
Other Operating Expenses
Total Operating Expenses
+ 1.0
Other Operating Expenses
Income Before Tax
+ 1.0
Net Income From Continuing Ops
Ebitda
+ 1.0
Ebit

High Negative Relationship

Total Operating Expenses
- 0.98
Operating Income
Operating Income
- 0.98
Other Operating Expenses
Total Operating Expenses
- 0.97
Ebitda
Ebitda
- 0.97
Research Development
Total Operating Expenses
- 0.97
Ebit
Research Development
- 0.97
Ebit

Moleculin Biotech income statement Accounts

201920202021202220232024 (projected)
Interest Income4.1M13K306K240K1.2M965.1K
Depreciation And Amortization185K285K260K222K127K120.7K
Interest Expense8.2M13K7.1M1.6M1.9M2.3M
Selling General Administrative6.3M6.8M8.4M11.7M10.0M6.9M
Gross Profit(185K)(285K)(260K)(222K)(127K)(133.4K)
Other Operating Expenses17.5M19.7M23.0M30.6M29.6M18.2M
Operating Income(17.5M)(19.7M)(23.0M)(30.6M)(29.6M)(28.1M)
Net Income From Continuing Ops(13.2M)(17.4M)(15.9M)(29.0M)(26.3M)(25.0M)
Ebit(21.6M)(19.8M)(23.1M)(30.7M)(29.6M)(28.1M)
Research Development11.0M12.8M14.4M19.0M19.5M11.3M
Ebitda(21.4M)(19.5M)(22.8M)(30.5M)(29.5M)(28.0M)
Cost Of Revenue185K285K260K222K127K143.1K
Total Operating Expenses17.5M19.7M23.0M30.6M29.6M18.2M
Income Before Tax(13.4M)(17.4M)(15.9M)(29.0M)(29.8M)(28.3M)
Total Other Income Expense Net4.1M2.4M7.1M1.6M(138K)(131.1K)
Net Income Applicable To Common Shares(11.9M)(13.2M)(17.4M)(15.9M)(14.3M)(15.0M)
Net Income(13.2M)(15.0M)(8.9M)(27.4M)(29.8M)(28.3M)
Income Tax Expense(229K)(2.4M)(7.0M)(1.6M)(1.5M)(1.5M)
Reconciled Depreciation199K200K164K130K124K141.9K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Additional Tools for Moleculin Stock Analysis

When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY